Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.
Schatz-Jakobsen, J.A., Zhang, Y., Johnson, K., Neill, A., Sheridan, D., Andersen, G.R.(2016) J Immunol 197: 337-344
- PubMed: 27194791 
- DOI: 10.4049/jimmunol.1600280
- Primary Citation of Related Structures:  
5I5K - PubMed Abstract: 
Eculizumab is a humanized mAb approved for treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Eculizumab binds complement component C5 and prevents its cleavage by C5 convertases, inhibiting release of both the proinflammatory metabolite C5a and formation of the membrane attack complex via C5b ...